{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:18:31Z","timestamp":1767845911278,"version":"3.49.0"},"reference-count":5,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1112,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1111\/j.1524-4741.2012.01293.x","type":"journal-article","created":{"date-parts":[[2012,8,15]],"date-time":"2012-08-15T10:59:13Z","timestamp":1345028353000},"page":"502-503","source":"Crossref","is-referenced-by-count":5,"title":["Retrobulbar Optic Neuritis in a Bevacizumab-Treated Patient with Metastatic Breast Cancer"],"prefix":"10.1155","volume":"18","author":[{"given":"Yan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2012,8,15]]},"reference":[{"key":"10.1111\/j.1524-4741.2012.01293.x-BIB1|cit1","unstructured":"Miller K Wang M Gralow J et\u00a0al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100)"},{"issue":"21 Suppl. 5","key":"10.1111\/j.1524-4741.2012.01293.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/ajhp\/61.suppl_5.S21","article-title":"Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor","volume":"61","author":"Ignoffo","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/j.1524-4741.2012.01293.x-BIB3|cit3","first-page":"327","article-title":"Bevacizumab in the treatment of metastatic breast cancer","volume":"23","author":"Traina","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"10.1111\/j.1524-4741.2012.01293.x-BIB4|cit4","volume-title":"Avastin (Bevacizumab) Package Insert","year":"2008"},{"key":"10.1111\/j.1524-4741.2012.01293.x-BIB5|cit5","first-page":"67","article-title":"Optic neuritis","volume":"8","author":"Vaphiades","year":"2007","journal-title":"Compr Ophthalmol Update"}],"container-title":["The Breast Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1524-4741.2012.01293.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1524-4741.2012.01293.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:26:50Z","timestamp":1643351210000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1524-4741.2012.01293.x"}},"subtitle":["LETTER TO THE EDITOR"],"short-title":[],"issued":{"date-parts":[[2012,8,15]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1524-4741.2012.01293.x","relation":{},"ISSN":["1075-122X"],"issn-type":[{"value":"1075-122X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8,15]]}}}